director from life science venture capitals, page-3

Biota Holders,
Two additional things I lke about the media release:

1: "vapendavir, a potent, oral broad spectrum capsid inhibitor of enteroviruses, including human rhinovirus." - Vapendavir remains "up in lights" where it should be. It has huge potential as a treatment for the "common cold" and
2:Russel Plumb, the new CEO as contact is "front and centre" of "selling the sizzle".

Hold on to your seats.

Regards
Kangaroo1


"The Company currently has two Phase 2 clinical-stage product candidates in development: Laninamivir octanoate, which the Company is developing for the treatment of influenza A and B infections in the U.S. through a contract with the U.S. Office of Biomedical Advanced Research and Development Authority (BARDA) that provides up to $231 million in financial support to complete its clinical development; and vapendavir, a potent, oral broad spectrum capsid inhibitor of enteroviruses, including human rhinovirus. In addition to these clinical-stage programs, the Company has preclinical programs focused on developing treatments for respiratory syncytial virus and gram-negative, multi-drug resistant bacterial infections. For additional information about the Company, please visit www.biotapharma.com.

Biota is a registered trademark of Biota Holdings Limited.

Contact:

Russell H. Plumb
President and CEO
(678) 221-3351
[email protected]